VIRALYTICS LIMITED - Announcements

Currently unlisted. Add to my watchlist

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

Filters [Clear]

Price Sensitive: Yes

VLA	Suspension from Official Quotation at close 05/06/18	PRICE SENSITIVE	05/06/18	227.31KB	Share
VLA	Federal Court of Australia approves scheme of arrangement	PRICE SENSITIVE	04/06/18	92.36KB	Share
VLA	VLA Shareholders Vote in Favour of Scheme of Arrangement	PRICE SENSITIVE	28/05/18	98.56KB	Share
VLA	Update on Scheme of Arrangement	PRICE SENSITIVE	23/05/18	55.8KB	Share
VLA	Appendix 4C - quarterly	PRICE SENSITIVE	24/04/18		Share
VLA	Court approves convening of scheme meeting	PRICE SENSITIVE	20/04/18		Share
VLA	New CAVATAK Data at International Oncolytic Virus Conference	PRICE SENSITIVE	11/04/18		Share
VLA	Appendix 4D Half Yearly Report and Accounts	PRICE SENSITIVE	26/02/18		Share
VLA	MSD and Viralytics Announce Acquisition Agreement	PRICE SENSITIVE	21/02/18		Share
VLA	Appendix 4C - quarterly	PRICE SENSITIVE	24/01/18		Share
VLA	Viralytics Receives $6.4 Million R&D Tax Incentive	PRICE SENSITIVE	08/01/18		Share
VLA	$29.6m Equity Placement to Lepu Medical Group of China	PRICE SENSITIVE	05/01/18		Share
VLA	Trading Halt	PRICE SENSITIVE	04/01/18		Share
VLA	New Data at SITC Meeting. Further Studies Announced	PRICE SENSITIVE	13/11/17		Share
VLA	Appendix 4C - quarterly	PRICE SENSITIVE	25/10/17		Share
VLA	Appendix 4E and Full Year Statutory Accounts	PRICE SENSITIVE	18/08/17		Share
VLA	Appendix 4C - quarterly	PRICE SENSITIVE	18/07/17		Share
VLA	Update on MITCI and KEYNOTE 200 trials at ASCO Ann Meeting	PRICE SENSITIVE	06/06/17		Share
VLA	Appendix 4C - quarterly	PRICE SENSITIVE	11/04/17		Share
VLA	Progress Report on KEYNOTE 200 at AACR Podium	PRICE SENSITIVE	05/04/17		Share
VLA	Promising Results MITCI Melanoma Trial at AACR Podium	PRICE SENSITIVE	05/04/17		Share
VLA	Promising Results CAPRA Melanoma Trial expand to 50 patients	PRICE SENSITIVE	04/04/17		Share
VLA	Viralytics to Present New CAVATAK Clinical Data at AACR	PRICE SENSITIVE	02/03/17		Share
VLA	Appendix 4D Half Yearly Report and Accounts	PRICE SENSITIVE	22/02/17		Share
VLA	Viralytics Receives $4.3 Million R&D Tax Incentive	PRICE SENSITIVE	13/02/17		Share
VLA	Appendix 4C - quarterly	PRICE SENSITIVE	27/01/17		Share
VLA	Promising Advanced Melanoma Results - KEYTRUDA Combination	PRICE SENSITIVE	14/11/16		Share
VLA	Appendix 4C - quarterly-VLA.AX	PRICE SENSITIVE	26/10/16		Share
VLA	CAVATAK YERVOY Promising Results in Advanced Melanoma - ESMO-VLA.AX	PRICE SENSITIVE	10/10/16		Share
VLA	VLA update on CAVATAK KEYTRUDA Combination trials - ESMO-VLA.AX	PRICE SENSITIVE	10/10/16		Share
VLA	VLA presents at Oncolytic Virus Therapeutics Conference-VLA.AX	PRICE SENSITIVE	04/10/16		Share
VLA	Appendix 4E and Full Year Statutory Accounts-VLA.AX	PRICE SENSITIVE	28/08/16		Share
VLA	Appendix 4E and Full Year Statutory Accounts-VLA.AX	PRICE SENSITIVE	25/08/16		Share
VLA	Appendix 4C - quarterly-VLA.AX	PRICE SENSITIVE	26/07/16		Share
VLA	Updated Clinical Trial Data Presented at ASCO Annual Meeting-VLA.AX	PRICE SENSITIVE	06/06/16		Share
VLA	Appendix 4C - quarterly-VLA.AX	PRICE SENSITIVE	28/04/16		Share
VLA	Positive Clinical Data from CAVATAK and YERVOY Combination-VLA.AX	PRICE SENSITIVE	19/04/16		Share
VLA	CAVATAK Immune Activity in Tumour Micro-environment-VLA.AX	PRICE SENSITIVE	19/04/16		Share
VLA	Checkpoint Combination active in Preclinical Lung, Melanoma-VLA.AX	PRICE SENSITIVE	19/04/16		Share
VLA	Positive CAVATAK Clinical Data Presented at EAU Congress	PRICE SENSITIVE	15/03/16		Share
VLA	Appendix 4D Half Yearly Report and Accounts	PRICE SENSITIVE	23/02/16		Share
VLA	Appendix 4C - quarterly	PRICE SENSITIVE	27/01/16		Share
VLA	Viralytics completes $28 million Placement - SPP to follow	PRICE SENSITIVE	14/12/15		Share
VLA	Trading Halt	PRICE SENSITIVE	10/12/15		Share
VLA	Viralytics Receives $2.9 Million R&D Tax Incentive	PRICE SENSITIVE	09/12/15		Share
VLA	Positive CAVATAK Clinical Data Presented at 2015 SITC	PRICE SENSITIVE	09/11/15		Share
VLA	Viralytics and Merck Collaborate in Lung and Bladder Cancer	PRICE SENSITIVE	06/11/15		Share
VLA	Appendix 4C - quarterly	PRICE SENSITIVE	28/10/15		Share
VLA	VLA initiates Clinical Trial of CAVATAK and PD-1 Combination	PRICE SENSITIVE	28/09/15		Share
VLA	Viralytics Presents Data at European Cancer Congress	PRICE SENSITIVE	28/09/15		Share
VLA	Appendix 4E and Full Year Statutory Accounts	PRICE SENSITIVE	26/08/15		Share
VLA	Appendix 4C - quarterly	PRICE SENSITIVE	21/07/15		Share
VLA	Positive final results from CAVATAK Phase 2 Melanoma Trial	PRICE SENSITIVE	02/06/15		Share
VLA	Appendix 4C - quarterly	PRICE SENSITIVE	28/04/15		Share
VLA	AACR Annual Meeting - Update on CALM & STORM Trials	PRICE SENSITIVE	21/04/15		Share
VLA	Response to Price Query Letter	PRICE SENSITIVE	27/02/15		Share
VLA	Half Yearly Report and Accounts	PRICE SENSITIVE	17/02/15		Share
VLA	VLA commences Clinical Trial of CAVATAK in Bladder Cancer	PRICE SENSITIVE	27/01/15		Share
VLA	Appendix 4C - quarterly	PRICE SENSITIVE	22/01/15		Share
VLA	Commencement of Checkpoint Inhibitor Combination trial	PRICE SENSITIVE	04/12/14		Share
VLA	Viralytics Receives $2.5 Million R&D Tax Incentive	PRICE SENSITIVE	02/12/14		Share
VLA	Approval for CAVATAK Clinical Trial - Bladder Cancer	PRICE SENSITIVE	14/11/14		Share
VLA	Positive CAVATAK Combination Data Presented at US Meeting	PRICE SENSITIVE	07/11/14		Share
VLA	Appendix 4C - quarterly	PRICE SENSITIVE	24/10/14		Share
VLA	CAVATAK Immunotherapy Combo shows more Anti-cancer Activity	PRICE SENSITIVE	30/09/14		Share
VLA	Updated positive data from Phase 2 Melanoma trial of CAVATAK	PRICE SENSITIVE	29/09/14		Share
VLA	Updated CAVATAK Results to be presented at ESMO Congress	PRICE SENSITIVE	17/09/14		Share
VLA	Appendix 4E and Financial Report	PRICE SENSITIVE	27/08/14		Share
VLA	Appendix 4C - quarterly	PRICE SENSITIVE	22/07/14		Share
VLA	Viralytics - Progress in CAVATAK Phase 2 Melanoma Trial	PRICE SENSITIVE	03/06/14		Share
VLA	Appendix 4C - quarterly	PRICE SENSITIVE	29/04/14		Share
VLA	CAVATAK activity in lung cancer - international conference	PRICE SENSITIVE	14/04/14		Share
VLA	Positive Interim Phase 2 Trial Results for CAVATAK	PRICE SENSITIVE	08/04/14		Share
VLA	Viralytics completes $27 million Fund Raising	PRICE SENSITIVE	13/03/14		Share
VLA	Viralytics commences STORM phase 1/2 clinical trial	PRICE SENSITIVE	06/03/14		Share
VLA	Half Yearly Report and Accounts	PRICE SENSITIVE	19/02/14		Share
VLA	Viralytics expands patent coverage in the US	PRICE SENSITIVE	04/02/14		Share
VLA	Viralytics - Entitlement Offer - Information Booklet	PRICE SENSITIVE	30/01/14		Share
VLA	Viralytics - Capital Raising up to $27 million	PRICE SENSITIVE	30/01/14		Share
VLA	Appendix 4C - quarterly	PRICE SENSITIVE	29/01/14		Share
VLA	Trading Halt	PRICE SENSITIVE	28/01/14		Share
VLA	Target enrolment achieved - CAVATAK Phase 2 Melanoma Trial	PRICE SENSITIVE	08/01/14		Share
VLA	Further strong progress in CAVATAK phase 2 CALM trial	PRICE SENSITIVE	08/11/13		Share
VLA	Viralytics receives $1.9 million R&D Tax Incentive	PRICE SENSITIVE	23/10/13		Share
VLA	Appendix 4C - quarterly	PRICE SENSITIVE	18/10/13		Share
VLA	Primary Endpoint Achieved in CAVATAK Phase 2 Melanoma Trial	PRICE SENSITIVE	18/09/13		Share
VLA	Viralytics receives MHRA approval for UK Clinical Trial	PRICE SENSITIVE	11/09/13		Share
VLA	Response to ASX Price Query	PRICE SENSITIVE	30/08/13		Share
VLA	Viralytics Full Year Financial Results	PRICE SENSITIVE	28/08/13		Share
VLA	Viralytics Patent Coverage Expanded	PRICE SENSITIVE	07/08/13		Share
VLA	Strong interim results of CAVATAK in Phase 2 Trial	PRICE SENSITIVE	19/07/13		Share
VLA	Appendix 4C - quarterly	PRICE SENSITIVE	17/07/13		Share
VLA	CAVATAK anticancer activity in bladder cancer model	PRICE SENSITIVE	18/06/13		Share
VLA	ASCO Poster and CALM Trial Milestone Achieved	PRICE SENSITIVE	04/06/13		Share
VLA	Appendix 4C - quarterly	PRICE SENSITIVE	16/04/13		Share
VLA	Positive results for Viralytics CAVATAK phase 1 IV Study	PRICE SENSITIVE	09/04/13		Share
VLA	Viralytics comment on results from Amgen Phase 3 trial	PRICE SENSITIVE	22/03/13		Share
VLA	Acceleration of Patient Recruitment in Phase 2 Study	PRICE SENSITIVE	21/03/13		Share
VLA	Appendix 4D and Half Year Report	PRICE SENSITIVE	18/02/13		Share
VLA	Appendix 4C - quarterly	PRICE SENSITIVE	29/01/13		Share

VLA Suspension from Official Quotation at close 05/06/18
05/06/18	PRICE SENSITIVE	227.31KB	Share
VLA Federal Court of Australia approves scheme of arrangement
04/06/18	PRICE SENSITIVE	92.36KB	Share
VLA VLA Shareholders Vote in Favour of Scheme of Arrangement
28/05/18	PRICE SENSITIVE	98.56KB	Share
VLA Update on Scheme of Arrangement
23/05/18	PRICE SENSITIVE	55.8KB	Share
VLA Appendix 4C - quarterly
24/04/18	PRICE SENSITIVE		Share
VLA Court approves convening of scheme meeting
20/04/18	PRICE SENSITIVE		Share
VLA New CAVATAK Data at International Oncolytic Virus Conference
11/04/18	PRICE SENSITIVE		Share
VLA Appendix 4D Half Yearly Report and Accounts
26/02/18	PRICE SENSITIVE		Share
VLA MSD and Viralytics Announce Acquisition Agreement
21/02/18	PRICE SENSITIVE		Share
VLA Appendix 4C - quarterly
24/01/18	PRICE SENSITIVE		Share
VLA Viralytics Receives $6.4 Million R&D Tax Incentive
08/01/18	PRICE SENSITIVE		Share
VLA $29.6m Equity Placement to Lepu Medical Group of China
05/01/18	PRICE SENSITIVE		Share
VLA Trading Halt
04/01/18	PRICE SENSITIVE		Share
VLA New Data at SITC Meeting. Further Studies Announced
13/11/17	PRICE SENSITIVE		Share
VLA Appendix 4C - quarterly
25/10/17	PRICE SENSITIVE		Share
VLA Appendix 4E and Full Year Statutory Accounts
18/08/17	PRICE SENSITIVE		Share
VLA Appendix 4C - quarterly
18/07/17	PRICE SENSITIVE		Share
VLA Update on MITCI and KEYNOTE 200 trials at ASCO Ann Meeting
06/06/17	PRICE SENSITIVE		Share
VLA Appendix 4C - quarterly
11/04/17	PRICE SENSITIVE		Share
VLA Progress Report on KEYNOTE 200 at AACR Podium
05/04/17	PRICE SENSITIVE		Share
VLA Promising Results MITCI Melanoma Trial at AACR Podium
05/04/17	PRICE SENSITIVE		Share
VLA Promising Results CAPRA Melanoma Trial expand to 50 patients
04/04/17	PRICE SENSITIVE		Share
VLA Viralytics to Present New CAVATAK Clinical Data at AACR
02/03/17	PRICE SENSITIVE		Share
VLA Appendix 4D Half Yearly Report and Accounts
22/02/17	PRICE SENSITIVE		Share
VLA Viralytics Receives $4.3 Million R&D Tax Incentive
13/02/17	PRICE SENSITIVE		Share
VLA Appendix 4C - quarterly
27/01/17	PRICE SENSITIVE		Share
VLA Promising Advanced Melanoma Results - KEYTRUDA Combination
14/11/16	PRICE SENSITIVE		Share
VLA Appendix 4C - quarterly-VLA.AX
26/10/16	PRICE SENSITIVE		Share
VLA CAVATAK YERVOY Promising Results in Advanced Melanoma - ESMO-VLA.AX
10/10/16	PRICE SENSITIVE		Share
VLA VLA update on CAVATAK KEYTRUDA Combination trials - ESMO-VLA.AX
10/10/16	PRICE SENSITIVE		Share
VLA VLA presents at Oncolytic Virus Therapeutics Conference-VLA.AX
04/10/16	PRICE SENSITIVE		Share
VLA Appendix 4E and Full Year Statutory Accounts-VLA.AX
28/08/16	PRICE SENSITIVE		Share
VLA Appendix 4E and Full Year Statutory Accounts-VLA.AX
25/08/16	PRICE SENSITIVE		Share
VLA Appendix 4C - quarterly-VLA.AX
26/07/16	PRICE SENSITIVE		Share
VLA Updated Clinical Trial Data Presented at ASCO Annual Meeting-VLA.AX
06/06/16	PRICE SENSITIVE		Share
VLA Appendix 4C - quarterly-VLA.AX
28/04/16	PRICE SENSITIVE		Share
VLA Positive Clinical Data from CAVATAK and YERVOY Combination-VLA.AX
19/04/16	PRICE SENSITIVE		Share
VLA CAVATAK Immune Activity in Tumour Micro-environment-VLA.AX
19/04/16	PRICE SENSITIVE		Share
VLA Checkpoint Combination active in Preclinical Lung, Melanoma-VLA.AX
19/04/16	PRICE SENSITIVE		Share
VLA Positive CAVATAK Clinical Data Presented at EAU Congress
15/03/16	PRICE SENSITIVE		Share
VLA Appendix 4D Half Yearly Report and Accounts
23/02/16	PRICE SENSITIVE		Share
VLA Appendix 4C - quarterly
27/01/16	PRICE SENSITIVE		Share
VLA Viralytics completes $28 million Placement - SPP to follow
14/12/15	PRICE SENSITIVE		Share
VLA Trading Halt
10/12/15	PRICE SENSITIVE		Share
VLA Viralytics Receives $2.9 Million R&D Tax Incentive
09/12/15	PRICE SENSITIVE		Share
VLA Positive CAVATAK Clinical Data Presented at 2015 SITC
09/11/15	PRICE SENSITIVE		Share
VLA Viralytics and Merck Collaborate in Lung and Bladder Cancer
06/11/15	PRICE SENSITIVE		Share
VLA Appendix 4C - quarterly
28/10/15	PRICE SENSITIVE		Share
VLA VLA initiates Clinical Trial of CAVATAK and PD-1 Combination
28/09/15	PRICE SENSITIVE		Share
VLA Viralytics Presents Data at European Cancer Congress
28/09/15	PRICE SENSITIVE		Share
VLA Appendix 4E and Full Year Statutory Accounts
26/08/15	PRICE SENSITIVE		Share
VLA Appendix 4C - quarterly
21/07/15	PRICE SENSITIVE		Share
VLA Positive final results from CAVATAK Phase 2 Melanoma Trial
02/06/15	PRICE SENSITIVE		Share
VLA Appendix 4C - quarterly
28/04/15	PRICE SENSITIVE		Share
VLA AACR Annual Meeting - Update on CALM & STORM Trials
21/04/15	PRICE SENSITIVE		Share
VLA Response to Price Query Letter
27/02/15	PRICE SENSITIVE		Share
VLA Half Yearly Report and Accounts
17/02/15	PRICE SENSITIVE		Share
VLA VLA commences Clinical Trial of CAVATAK in Bladder Cancer
27/01/15	PRICE SENSITIVE		Share
VLA Appendix 4C - quarterly
22/01/15	PRICE SENSITIVE		Share
VLA Commencement of Checkpoint Inhibitor Combination trial
04/12/14	PRICE SENSITIVE		Share
VLA Viralytics Receives $2.5 Million R&D Tax Incentive
02/12/14	PRICE SENSITIVE		Share
VLA Approval for CAVATAK Clinical Trial - Bladder Cancer
14/11/14	PRICE SENSITIVE		Share
VLA Positive CAVATAK Combination Data Presented at US Meeting
07/11/14	PRICE SENSITIVE		Share
VLA Appendix 4C - quarterly
24/10/14	PRICE SENSITIVE		Share
VLA CAVATAK Immunotherapy Combo shows more Anti-cancer Activity
30/09/14	PRICE SENSITIVE		Share
VLA Updated positive data from Phase 2 Melanoma trial of CAVATAK
29/09/14	PRICE SENSITIVE		Share
VLA Updated CAVATAK Results to be presented at ESMO Congress
17/09/14	PRICE SENSITIVE		Share
VLA Appendix 4E and Financial Report
27/08/14	PRICE SENSITIVE		Share
VLA Appendix 4C - quarterly
22/07/14	PRICE SENSITIVE		Share
VLAViralytics - Progress in CAVATAK Phase 2 Melanoma Trial
03/06/14	PRICE SENSITIVE		Share
VLAAppendix 4C - quarterly
29/04/14	PRICE SENSITIVE		Share
VLACAVATAK activity in lung cancer - international conference
14/04/14	PRICE SENSITIVE		Share
VLAPositive Interim Phase 2 Trial Results for CAVATAK
08/04/14	PRICE SENSITIVE		Share
VLAViralytics completes $27 million Fund Raising
13/03/14	PRICE SENSITIVE		Share
VLAViralytics commences STORM phase 1/2 clinical trial
06/03/14	PRICE SENSITIVE		Share
VLAHalf Yearly Report and Accounts
19/02/14	PRICE SENSITIVE		Share
VLAViralytics expands patent coverage in the US
04/02/14	PRICE SENSITIVE		Share
VLAViralytics - Entitlement Offer - Information Booklet
30/01/14	PRICE SENSITIVE		Share
VLAViralytics - Capital Raising up to $27 million
30/01/14	PRICE SENSITIVE		Share
VLAAppendix 4C - quarterly
29/01/14	PRICE SENSITIVE		Share
VLATrading Halt
28/01/14	PRICE SENSITIVE		Share
VLATarget enrolment achieved - CAVATAK Phase 2 Melanoma Trial
08/01/14	PRICE SENSITIVE		Share
VLAFurther strong progress in CAVATAK phase 2 CALM trial
08/11/13	PRICE SENSITIVE		Share
VLAViralytics receives $1.9 million R&D Tax Incentive
23/10/13	PRICE SENSITIVE		Share
VLAAppendix 4C - quarterly
18/10/13	PRICE SENSITIVE		Share
VLAPrimary Endpoint Achieved in CAVATAK Phase 2 Melanoma Trial
18/09/13	PRICE SENSITIVE		Share
VLAViralytics receives MHRA approval for UK Clinical Trial
11/09/13	PRICE SENSITIVE		Share
VLAResponse to ASX Price Query
30/08/13	PRICE SENSITIVE		Share
VLAViralytics Full Year Financial Results
28/08/13	PRICE SENSITIVE		Share
VLAViralytics Patent Coverage Expanded
07/08/13	PRICE SENSITIVE		Share
VLAStrong interim results of CAVATAK in Phase 2 Trial
19/07/13	PRICE SENSITIVE		Share
VLAAppendix 4C - quarterly
17/07/13	PRICE SENSITIVE		Share
VLACAVATAK anticancer activity in bladder cancer model
18/06/13	PRICE SENSITIVE		Share
VLAASCO Poster and CALM Trial Milestone Achieved
04/06/13	PRICE SENSITIVE		Share
VLAAppendix 4C - quarterly
16/04/13	PRICE SENSITIVE		Share
VLAPositive results for Viralytics CAVATAK phase 1 IV Study
09/04/13	PRICE SENSITIVE		Share
VLAViralytics comment on results from Amgen Phase 3 trial
22/03/13	PRICE SENSITIVE		Share
VLAAcceleration of Patient Recruitment in Phase 2 Study
21/03/13	PRICE SENSITIVE		Share
VLAAppendix 4D and Half Year Report
18/02/13	PRICE SENSITIVE		Share
VLAAppendix 4C - quarterly
29/01/13	PRICE SENSITIVE		Share

REFRESH

VIRALYTICS LIMITED - Announcements

Corporate SpotlightNot Yet Available

Announcements

Top Stories

Corporate Spotlight
Not Yet Available